Use of Cidofovir in Progressive Multifocal Leukoencephalopathy

@inproceedings{SegarraNewnham2001UseOC,
  title={Use of Cidofovir in Progressive Multifocal Leukoencephalopathy},
  author={Marisel Segarra-Newnham and K M Vodolo},
  booktitle={The Annals of pharmacotherapy},
  year={2001}
}
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating illness caused by the JC virus, a polyomavirus that occurs in 4–5% of HIV-positive patients. Mortality is high, and no useful therapy has been identified. Highly active antiretroviral therapy (HAART) has been reported to be effective in halting progression of the disease in some, but not all, patients. Cidofovir has been shown to be active against polyomaviruses. OBJECTIVE: To review data on the use of… 

Tables from this paper

Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy
TLDR
A benefit for cidofovir in addition to HAART in the treatment of PML in HIV-infected patients could not be proven.
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV‐negative lymphoproliferative disorders: Impact of novel therapies
TLDR
Among patients treated with purine analogues, PML is more common in male patients with CD4 cell counts ≤0.2 × 109/L; the use of rituximab after HDT/HSCT seems to delay the onset of PML; and the prognosis is slightly better in transplant recipients.
Progressive Multifocal Leukoencephalopathy: What’s New?
TLDR
Findings on the pathogenesis of PML are reviewed and the encouraging case reports of novel treatments are reviewed, including immunomodulation and/or inhibition of viral replication.
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis
TLDR
In combination antiretroviral therapy-treated HIV-infected PML patients, cidofovir use did not influence PML-related mortality or residual disability and new treatments for AIDS-related PML are urgently needed.
Correlation Between Cidofovir-Associated Uveitis and Failing Immunorestoration During HAART
TLDR
Cidofovir-associated uveitis seems to occur more frequently in AIDS patients with retinitis in whom highly active antiretroviral therapy fails to restore immunity.
The Cidofovir Controversy
TLDR
This chapter will focus on the benefits and risks of employing cidofovir in the RRP patient population as well as suggested treatment algorithms.
Trichodysplasia of immunosuppression treated with oral valganciclovir.
Opportunistic Infections of the CNS in Patients with AIDS
TLDR
Effective treatments are available for toxoplasmosis and cryptococcosis, although adverse effects are common and some patients may not respond to therapy, and the efficacy of anticytomegalovirus therapy is poor and the toxicity significant.
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy
TLDR
A patient with AIDS-associated PML is reported with a marked clinical and neuroradiologic improvement after cidofovir was added to HAART, and short-term stabilization of PML has been described using this agent alone.
The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group.
  • I. Fong, E. Toma
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1995
TLDR
The correlations between CD4+ lymphocyte count, previous diagnosis of AIDS, treatment with cytarabine, and survival time are reported for 28 individuals for whom the diagnosis of PML was confirmed by histopathologic examination.
Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside.
TLDR
The authors suggest that ara-C and cidofovir, not antiretroviral therapy, caused improvement in their patient’s condition, but this conclusion is unfounded.
Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside.
TLDR
The authors point out that improvement in their patient's condition was not related to antiretroviral therapy because progressive multifocal leukoencephalopathy (PML) developed 3 months after this treatment was applied, which does not necessarily mean this treatment will fail in the long term.
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
TLDR
The observations suggest that PML can develop in patients who have shown clinical response to HAART, and that definitive therapy is still needed for PML.
Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.
TLDR
This study of a large cohort of patients diagnosed with PML provides evidence that a combination antiretroviral regimen, especially one including PI, confers marked survival benefits.
Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.
TLDR
Cytarabine administered either intravenously or intrathecally does not improve the prognosis of HIV-infected patients with progressive multifocal leukoencephalopathy who are treated with the antiretroviral agents, nor does high-dose antireTroviral therapy alone appear to improve survival over that reported in untreated patients.
Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy.
TLDR
The clinical and virological outcome of human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy treated with cytarabine is described and the concentration of JC virus in CSF showed a correlation with clinical outcome.
Activities of various compounds against murine and primate polyomaviruses
TLDR
Cidofovir [HPMPC; (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] and its cyclic counterpart emerged as the most selective antipolyomavirus agents and deserves further evaluation as a candidate drug for polyomvirus infections in the immunocompromised host.
...
1
2
3
...